neoadjuvant docetaxel, oxaliplatin and S-1 therapy for large type 3 or type 4 gastric cancer

A phase II trial of neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer - OGSG1902

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051190060

Enrollment

Registered

2019-10-11

Start date

2019-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Preoperative chemotherapy with Docetaxel, Oxaliplatin, and S-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histological proven adenocarcinoma 2) Borrmann type 4 or large (8cm or more by Enhanced abdominal CT or gastrointestinal endoscopy) type 3 3) No peritoneal metastasis (CY0 or CY1, and P0) by laparoscopy and CT within 28days.No sign of distant metastasis including liver metastasis or paraaortic lymph node metastasis 4) Length of esophageal invasion less or equal to 3cm by image examination within 28 days 5) Age between 20 and 80 at registration 6) Performance Status(ECOG):0,1 7) No prior treatment of chemotherapy or radiation therapy 8) Adequate organ function 9) Fair oral intake with or without bypass surgery 10) HER2 negative or not examined 11) Written informed consent from patient

Exclusion criteria

Exclusion criteria: 1) Synchronous or metachronous (within 5 years) malignancies 2) Infectious disease requiring systemic treatment(over 38 degrees Celsius) 3) During pregnancy, postparturition, or during lactation 4) Severe mental disease 5) History of unstable angina pectoris within three weeks or myocardial infarction within six months before registration 6) Receiving continuous systemic corticosteroid or immunosuppressant treatment 7) Under treatment with flucytosine, phenytoin, or warfarin 8) Poorly controlled valve disease, dilated or hypertrophic cardiomyopathy 9) HBs antigen positive 10) Interstitial pneumonia, pulmonary fibrosis, or severe emphysema based on chest CT 11) Poorly controlled hypertension or diabetes 12) Patients judged inappropriate for the study by thephysicians

Design outcomes

Primary

Measure	Time frame
the 3-year progression free survival rate	—

Secondary

Measure	Time frame
progression free survival, overall survival, pathological response rate, response rate, completion rate of neoadjuvant chemotherapy, R0 resection rate, completion rate of surgery, completion rate of protocol treatment, complete response rate of peritoneal cytology (CY), incidence of toxicities, assessment of nutrition	—

Contacts

Public ContactRyo TANAKA

Osaka Medical and Pharmaceutical University Hospital

ryo.tanaka@ompu.ac.jp+81-72-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026